Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis

Primary analysis of JUMP, a phase 3b, expanded‐access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts

(2020) Haifa Kathrin Al‐Ali et al.   BRITISH JOURNAL OF HAEMATOLOGY

The role of allogeneic stem-cell transplant in myelofibrosis in the era of JAK inhibitors: a case-based review

(2019) Mario Tiribelli et al.   BONE MARROW TRANSPLANTATION

Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis

(2019) Francesca Palandri et al.   CANCER

Ruxolitinib Rechallenge Can Improve Constitutional Symptoms and Splenomegaly in Patients with Myelofibrosis: A Case Series

(2018) Aaron Gerds et al.   Clinical Lymphoma Myeloma & Leukemia

Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients

(2018) Francesca Palandri et al.   LEUKEMIA RESEARCH

Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis

(2017) Francesca Palandri et al.   Oncotarget

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors

(2016) Mohamed Shanavas et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation

(2014) Yan Beauverd et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Ruxolitinib Withdrawal Syndrome Leading to Tumor Lysis

(2013) Tong Dai et al.   JOURNAL OF CLINICAL ONCOLOGY

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

(2012) Claire Harrison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Serious Adverse Events During Ruxolitinib Treatment Discontinuation in Patients With Myelofibrosis

(2011) Ayalew Tefferi et al.   MAYO CLINIC PROCEEDINGS

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

(2010) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE